Vystar Adds Fluid Energy Conversion Into Planned RxAir Spin-Off
September 20, 2021 08:30 ET
|
Vystar Corp.
FEC patented technology has potential for applications in multiple industriesFEC to prioritize air and water purification R&D Worcester, MA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Vystar®...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
September 16, 2021 07:30 ET
|
Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Vystar Details Preliminary Plans for RxAir Spin Off as Shareholder Dividend
August 05, 2021 08:00 ET
|
Vystar Corp.
Separation of RxAir® business offers pure-play investment opportunityVystar shareholders on the Record Date of January 5, 2022 to qualify for dividend of RxAir NewCo shares Worcester,...
AB Science annonce la publication d’un article dans la revue de renommée mondiale Science qui confirme le potentiel du masitinib comme traitement de la Covid-19 avec une activité antivirale contre le SARS-CoV-2 et tous ses variants testés
July 20, 2021 12:08 ET
|
AB Science
COMMUNIQUE DE PRESSE PUBLICATION DANS LA REVUE DE RENOMMÉE MONDIALE SCIENCE CONFIRMANT LE POTENTIEL DU MASITINIB COMME TRAITEMENT DE LA COVID-19 AVEC UNE ACTIVITÉ ANTIVIRALE CONTRE LE SARS-COV-2...
AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern
July 20, 2021 12:08 ET
|
AB Science
PRESS RELEASE PUBLICATION IN THE WORLD-RENOWNED JOURNAL SCIENCE CONFIRMS POTENTIAL OF MASITINIB AS A TREATMENT OF COVID-19 WITH ANTI-VIRAL ACTIVITY AGAINST SARS-COV-2 AND ALL TESTED VARIANTS OF...
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium
June 18, 2021 09:30 ET
|
Innovation Pharmaceuticals Inc.
Presentation to be part of the “Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases” Breakout Session WAKEFIELD, Mass., June 18, 2021 (GLOBE NEWSWIRE)...
Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19
June 03, 2021 07:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full...
Vystar Partners with “Nothing in the Air” for RxAir Marketing, Advertising & Distribution
June 02, 2021 08:30 ET
|
Vystar Corp.
NITA president one of nation’s top 100 TV healthcare content producersLaunching ROKU Campaign June 3 Worcester, MA and PALM DESERT, CA, June 02, 2021 (GLOBE NEWSWIRE) -- Vystar® Corporation’s...
Vystar Posts Highest Revenue & Profit in Company History in First Quarter 2021
May 24, 2021 08:30 ET
|
Vystar Corp.
Increased revenue from RxAir® UV light air purifiers that destroy more than 99.6% of airborne viruses and bacteriaRecord revenue from Rotmans Furniture “Closing to Remodel” Sales EventIncreased gross...
Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
April 05, 2021 07:30 ET
|
Innovation Pharmaceuticals Inc.
Study drug dosing regimen to increase to 5 days (from 3 days) based on DMC recommendationEnrollment has reached 25 percent in the Company’s ~120-patient Phase 2 COVID-19 clinical trial WAKEFIELD,...